A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of Group B Streptococcus Vaccine (GBS NN/NN2 With Alhydrogel) in Elderly Participants Aged 55 to 75
Latest Information Update: 01 Jun 2024
At a glance
- Drugs Aluminium hydroxide (Primary) ; GBS NN (Primary)
- Indications Streptococcal infections
- Focus Adverse reactions
- Sponsors Minervax
Most Recent Events
- 27 May 2024 Status changed from active, no longer recruiting to completed.
- 27 Jun 2023 According to a Minervax media release, the first read-outs are anticipated in Q4, 2023.
- 08 Jun 2023 Status changed from recruiting to active, no longer recruiting.